Author:
Zarranz-Ventura Javier,Liew Gerald,Johnston Robert L.,Xing Wen,Akerele Toks,McKibbin Martin,Downey Louise,Natha Salim,Chakravarthy Usha,Bailey Clare,Khan Rehna,Antcliff Richard,Armstrong Stewart,Varma Atul,Kumar Vineeth,Tsaloumas Marie,Mandal Kaveri,Bunce Catey,Tufail Adnan
Reference41 articles.
1. Ranibizumab for neovascular age-related macular degeneration;Rosenfeld;N Engl J Med,2006
2. Ranibizumab versus verteporfin for neovascular age-related macular degeneration;Brown;N Engl J Med,2006
3. National Institute for Health and Care Excellence. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. NICE technology appraisal guidance 155. Last modified May 2012. Available at: http://www.nice.org.uk/nicemedia/live/12057/41719/41719.pdf. Accessed January 20, 2014.
4. Ranibizumab and bevacizumab for neovascular age-related macular degeneration;N Engl J Med,2011
5. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results;Martin;Ophthalmology,2012
Cited by
91 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献